It's a period in which Amryt completed the acquisition of Aegerion Pharmaceuticals Inc and saw the firm go from a single-product, Europe-focused business to an operation with infrastructure around the world and two orphan treatments.
Full interview: Amryt Pharma well positioned to become 'global leader in rare and orphan diseases'
Quick facts: Amryt Pharma PLC
Price: 165 GBX
Market Cap: £254.92 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE